Drug General Information
Drug ID	D0N2JI
Former ID	DIB000799
Drug Name	VAS-203
Synonyms	NOS inhibitor, Vasopharm; Nitric oxide synthase inhibitor, Vasopharm
Indication	Brain injury [ICD10:S09.90]		Phase 2	[548221]
Company	Vasopharm GmbH
Structure		Download 2D MOL 3D MOL
Canonical SMILES	c12NC(C(C(O)C)O)CNc1nc(nc2N)N
Target and Pathway
Target(s)	Nitric-oxide synthase, endothelial	Target Info	Inhibitor	[532781]
BioCyc Pathway	Citrulline-nitric oxide cycle
KEGG Pathway	Arginine and proline metabolism
	Metabolic pathways
	Calcium signaling pathway
	cGMP-PKG signaling pathway
	HIF-1 signaling pathway
	Sphingolipid signaling pathway
	PI3K-Akt signaling pathway
	VEGF signaling pathway
	Platelet activation
	Estrogen signaling pathway
	Oxytocin signaling pathway
NetPath Pathway	Wnt Signaling Pathway
PANTHER Pathway	Angiogenesis
	Endothelin signaling pathway
	Interleukin signaling pathway
	PI3 kinase pathway
	VEGF signaling pathway
Pathway Interaction Database	Plasma membrane estrogen receptor signaling
	Validated transcriptional targets of AP1 family members Fra1 and Fra2
	Angiopoietin receptor Tie2-mediated signaling
	Thromboxane A2 receptor signaling
	SHP2 signaling
	VEGFR1 specific signals
	Signaling events mediated by VEGFR1 and VEGFR2
	PAR1-mediated thrombin signaling events
Reactome	ROS production in response to bacteria
	Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
	eNOS activation
	Nitric oxide stimulates guanylate cyclase
	VEGFR2 mediated vascular permeability
WikiPathways	ACE Inhibitor Pathway
	EGF/EGFR Signaling Pathway
	Myometrial Relaxation and Contraction Pathways
	JAK/STAT
	Corticotropin-releasing hormone
	AGE/RAGE pathway
	Endothelin Pathways
	Leptin signaling pathway
	Effects of Nitric Oxide
	Metabolism of nitric oxide
	Angiogenesis
References
Ref 548221	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023224)
Ref 532781	Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.